These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36969835)

  • 1. Long way to go: Progress of orphan drug accessibility in China from 2017 to 2022.
    Liu J; Yu Y; Zhong M; Ma C; Shao R
    Front Pharmacol; 2023; 14():1138996. PubMed ID: 36969835
    [No Abstract]   [Full Text] [Related]  

  • 2. Evaluating the national system for rare diseases in China from the point of drug access: progress and challenges.
    Qiao L; Liu X; Shang J; Zuo W; Xu T; Qu J; Jiang J; Zhang B; Zhang S
    Orphanet J Rare Dis; 2022 Sep; 17(1):352. PubMed ID: 36088349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The availability and affordability of orphan drugs for rare diseases in China.
    Gong S; Wang Y; Pan X; Zhang L; Huang R; Chen X; Hu J; Xu Y; Jin S
    Orphanet J Rare Dis; 2016 Feb; 11():20. PubMed ID: 26920579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How Far Have We Come? Challenges to Orphan Drug Access in China, 2011-2017.
    Guan X; Zhang J; Man C; Ni B; Shi L
    J Pharm Sci; 2019 Jun; 108(6):2199-2205. PubMed ID: 30677418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Availability, cost and affordability of selected antibiotics and antiviral medicines against infectious diseases from 2013 to 2019 in Nanjing, China.
    Zhu Y; Xu X; Fang W; Wang Y; Dai H; Li X
    Trop Med Int Health; 2021 May; 26(5):518-529. PubMed ID: 33539605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient Access to Orphan Drugs Covered by Medical Insurance in China: Real-World Evidence From Patient Survey.
    Wang X; Li SC; Yue X; Li Y; Shi N; Zhao FL; Wu J
    Value Health Reg Issues; 2023 Mar; 34():71-77. PubMed ID: 36587572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orphan drug policy analysis in China.
    Liu M; Lu Y; Li J; Zhang Y; Zhang S; Liu Y
    Front Pharmacol; 2024; 15():1278710. PubMed ID: 38939834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The availability, price and affordability of antidiabetic drugs in Hubei province, China.
    Gong S; Cai H; Ding Y; Li W; Juan X; Peng J; Jin S
    Health Policy Plan; 2018 Oct; 33(8):937-947. PubMed ID: 30215707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accessibility of essential anticancer medicines for children in the Sichuan Province of China.
    Chen Z; Li S; Zou K; Li H; Zeng L; Lu X; Jia ZJ; Cheng G; Zhang L
    Front Public Health; 2022; 10():980969. PubMed ID: 36408013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating the budget impact of orphan medicines in Europe: 2010 - 2020.
    Schey C; Milanova T; Hutchings A
    Orphanet J Rare Dis; 2011 Sep; 6():62. PubMed ID: 21951518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Cross-Sectional Study of Price and Affordability of Drugs for Rare Diseases in Shandong Province, China.
    Mu Y; Song K; Song Y
    Int J Environ Res Public Health; 2022 Oct; 19(20):. PubMed ID: 36293897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Availability, Price and Affordability of Anticancer Medicines: Evidence from Two Cross-Sectional Surveys in the Jiangsu Province, China.
    Zhu Y; Wang Y; Sun X; Li X
    Int J Environ Res Public Health; 2019 Oct; 16(19):. PubMed ID: 31623326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A survey of availability, price and affordability of essential medicines from 2011 to 2016 in Chinese secondary and tertiary hospitals.
    Guan X; Hu H; Man C; Shi L
    Int J Equity Health; 2018 Oct; 17(1):158. PubMed ID: 30340587
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of the National Reimbursement Drug List Negotiation Policy on Accessibility of Anticancer Drugs in China: An Interrupted Time Series Study.
    Zhu H; Zhu J; Zhou Y; Shan L; Li C; Cui Y; Kang Z; Jiao M; Liu H; Gao L; Wu Q; Hao Y
    Front Public Health; 2022; 10():921093. PubMed ID: 35844892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Availability and Affordability of Therapeutic Monoclonal Antibodies After the New Medical Reform in Hubei Province, China.
    Ding YF; Zhang JW; Xia MJ; Wu GJ; Li WJ; Feng D; Gong SW
    Curr Med Sci; 2022 Dec; 42(6):1325-1333. PubMed ID: 36544039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis on the Marketing Trend and Approval Lag of Imported Orphan Drugs from 2010 to 2021 in China.
    Peng F; Zheng H
    Ther Innov Regul Sci; 2023 Nov; 57(6):1314-1321. PubMed ID: 37651044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Catastrophic expenditure and impoverishment of patients affected by 7 rare diseases in China.
    Xin XX; Guan XD; Shi LW
    Orphanet J Rare Dis; 2016 Jun; 11(1):74. PubMed ID: 27266878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Affordability Challenges to Value-Based Pricing: Mass Diseases, Orphan Diseases, and Cures.
    Danzon PM
    Value Health; 2018 Mar; 21(3):252-257. PubMed ID: 29566830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prices, availability, and affordability of national essential medicines in public primary hospitals: A cross-sectional survey in poverty-stricken rural areas in China.
    Xu R; Li S; Lv X; Xie X
    Int J Health Plann Manage; 2020 Mar; 35(2):545-557. PubMed ID: 31736154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drugs for rare diseases: mixed assessment in Europe.
    Prescrire Int; 2007 Feb; 16(87):36-42. PubMed ID: 17323539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.